About
Partner in Dechert's intellectual property group, focusing on patent law relating to biotechnology. Extensive experience representing biotech companies and investors in strategic international patent portfolio development and life cycle management, as well as non-infringement and invalidity analysis, post-grant proceedings and IP due diligence.
Practice areas
Patent LawBiotechnologyIntellectual PropertyPatent Portfolio DevelopmentLife Cycle ManagementNon-infringement AnalysisInvalidity AnalysisPost-grant ProceedingsIP Due DiligenceTherapeutic AntibodiesImmunotherapyGene TherapyDrug Delivery TechnologiesRNAi TechnologiesBayh-Dole Compliance
Office
Expertise
Therapeutic antibodies and antibody-like molecules for oncology, autoimmune, cardiovascular and infectious disease indicationsImmunotherapy, including CAR and recombinant TCR technologies, peptide-based vaccines and immune checkpoint antibodiesAntibody and TCR discovery and engineering technologiesGlycoengineering technologies, including antibody Fc glycoengineering technologiesViral delivery technologies, including lentiviral and AAV delivery technologiesGene therapy technologies, including gene replacement and gene editing technologiesBiocompatible drug delivery vehicles, including controlled release nanoparticle liposome technologiesDrug screening assaysRNAi technologiesBayh-Dole compliance in the acquisition or licensing of IP based upon NIH-funded research
Education
- University of Glasgow, B.Sc., Biochemistry
- University of London, Ph.D., Molecular Cell Biology
- Suffolk University Law School, J.D.